You are about to be redirected to a site intended for people with primary HLH or their caregivers.
You are being redirected to a third party website.
Sobi takes no responsibility for the content of this website.
For patients with primary hemophagocytic lymphohistiocytosis (HLH), a successful hematopoietic stem cell transplant (HSCT) is the ultimate goal. Meanwhile, keeping inflammatory symptoms under control with the proper treatment is crucial.1-3
Immediately bring the cytokine storm under control. Subsequent treatment depends on symptom presentation and confirmation of diagnosis.1-3
Condition the patient for HSCT in a way that optimizes their long-term prognosis.1
Data show that 50% of patients fail to reach HSCT due to inadequate response to conventional treatments.4
Over the past 25 years, few advancements have been made in targeted HLH therapy.5
Conventional treatments, which are not FDA-approved for primary HLH, are aimed at immune supression.5,6
When a patient responds unsatisfactorily to conventional treatment, cannot tolerate it, or relapses, there has been no standard alternative. HSCT is always the goal, but physicians may have little choice but to rush poorly conditioned patients into the procedure, or forgo transplant altogether.1,5,7
Gamifant® (emapalumab-lzsg) is the first and only treatment designed specifically for primary HLH.It works by targeting IFNγ, a central cytokine in the pathogenesis of the disease.8-10See how it works
Primary hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory condition that mostly affects children, but can also occur in adults and teenagers.1,5,11,12
Gamifant reduces the inflammatory symptoms of primary HLH by neutralizing IFNγ.8
Gamifant is given as an intravenous infusion twice a week until hematopoietic stem cell transplantation (HSCT) is performed.8
Download the Start Form now or contact Gamifant Patient Services at 833.597.6530.